2013
DOI: 10.1136/annrheumdis-2012-eular.1156
|View full text |Cite
|
Sign up to set email alerts
|

AB1158 Efficacy and security of anakinra treatment in patients with systemic-onset juvenil idiopathic arthritis: “Initial results from a register of two pediatric reumatologic units from spain”:

Abstract: Background Interleukin-1 (Il-1) is a critical cytokine for the pathogenesis of systemic JIA. Treatment with anakinra (Il-1 receptor antagonist) has been reported to be effective in some patients with systemic-onset juvenile idiopathic arthritis (SoJIA). Objectives To examine the safety and the efficacy of anakinra treatment in a cohort of SoJIA patients regarding clinical and biological data from two reference centers. Methods We retrospectively reviewed the medical records of 50 patients with SoJIA, treated… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles